Detalhe da pesquisa
1.
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Blood
; 143(16): 1616-1627, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38215395
2.
Statistical Considerations and Software for Designing Sequential, Multiple Assignment, Randomized Trials (SMART) with a Survival Final Endpoint.
J Biopharm Stat
; : 1-14, 2023 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37434437
3.
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
Blood
; 135(5): 371-380, 2020 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826241
4.
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
N Engl J Med
; 379(26): 2517-2528, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30501481
5.
Impact of the COVID-19 Pandemic on Cancer Clinical Trials.
Ann Surg Oncol
; 28(12): 7311-7316, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34236550
6.
Understanding Verbosity: Funding Source and the Length of Consent Forms for Cancer Clinical Trials.
J Cancer Educ
; 36(6): 1248-1252, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32385740
7.
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).
Oncologist
; 25(6): 523-531, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31872928
8.
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
N Engl J Med
; 377(5): 454-464, 2017 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28644114
9.
An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
J Biopharm Stat
; 29(2): 271-286, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30403559
10.
Application of multi-state models in cancer clinical trials.
Clin Trials
; 15(5): 489-498, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30035644
11.
Definitions and statistical properties of master protocols for personalized medicine in oncology.
J Biopharm Stat
; 28(2): 217-228, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-28877008
12.
Ibrutinib Regimens in Older Patients with Untreated CLL. Reply.
N Engl J Med
; 380(17): 1680-1681, 2019 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31018081
13.
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.
Hepatology
; 73 Suppl 1: 158-191, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32430997
14.
A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
Stat Med
; 36(1): 67-80, 2017 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27633877
15.
Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Clin Trials
; 14(6): 611-620, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28764555
16.
Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus.
Clin Gastroenterol Hepatol
; 13(4): 665-72.e1-4, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25218668
17.
High-Dose Glucocorticoids for Treating Sudden Hearing Loss: Cart before the Horse?
NEJM Evid
; 3(1): EVIDe2300296, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38320518
18.
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.
Gastroenterology
; 143(4): 917-26.e1, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22796132
19.
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Blood
; 118(11): 2970-5, 2011 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21690557
20.
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
Invest New Drugs
; 31(6): 1559-67, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24114122